Etoricoxib
From Ganfyd
rINN: Etoricoxib
Other Names
Arcoxia®
Pharmacological Information
Pharmacology Images
Web information on Etoricoxib
Relevant Clinical Literature
UK Guidance
Regulatory Literature
Other Literature
Please read pharmacological data limitations
Other Wikis
Medpedia on Etoricoxib (Less technical, good quality control)
Wikipedia on Etoricoxib (Less technical, ? quality control)
Contents |
Indication
- Pain and inflammation in osteoarthritis and rheumatoid arthritis
- Acute gout
Dose
- Osteoarthritis (over 16 years) 30-60mg daily
- Rheumatoid arthritis (over 16 years) 90mg once daily (presently limited efficacy data at 60mg dose now being studied)
- Acute gout 120mg once daily
- Ankylosing spondylitis 90mg once daily (presently limited efficacy data at 60mg dose now being studied -unlicensed indication as of June 2008 in EU)
Recommended not to use if BP > 140/90[1]
Side-effects
- Atrial fibrillation (appears to be drug specific)[2]
Commoner important
- Upper gastro-intestinal. All NSAIDs are associated with serious gastrointestinal side effects. For non-selective NSAIDs these were most common with azapropazone and least common with Ibuprofen. Selective cyclo-oxygenase-2 inhibitors are associated with a lower risk of gastrointestinal side effects
- Dyspepsia
- Haemorrhage
- Renal failure (especially in combination with diuretics and drugs acting on angiotensin system)
- Fluid retention
Rarer Important
- Cardiovascular events. This may be related to degree of cyclo-oxygenase-2 inhibition
- Asthma
- In chronic heart failure all NSAIDS have a dose-dependent increase in risk of death and increased risk of hospitalization with some such as diclofenac and coxibs having higher hazard ratios[3]
List of NSAID side-effects - many rare
Some NSAIDs are more likely to cause these side-effects than others but they all appear to be class side-effects
- Gastro-intestinal
- Gastritis
- Duodenitis
- Duodenal ulcer
- Gastric ulcer
- Oesophagitis
- Oesophageal ulcer
- Intestinal stricture
- Haemorrhage
- Colitis
- Diarrhoea
- Nausea
- Renal
- Failure
- Fluid retention/Oedema
- Papillary necrosis
- Interstitial fibrosis
- Hypersensitivity reactions
- Asthma
- Pulmonary eosinophilia
- Rashes
- Stephen-Johnson syndrome
- Toxic epidermal necrolysis
- Photosensitivity
- Nervous system
- Headache
- Dizziness
- Vertigo
- Nervousness
- Depression
- Drowsiness
- Insomnia
- Hearing disturbances
- Tinnitus
- Aseptic meningitis
- Aggravate Parkinsonism
- Other
- Haematuria
- Hepatic damage
- Alveolitis
- Pancreatitis
References
- ↑ EMEA Etoricoxib recommendations)June 2008
- ↑ Bäck M, Yin L, Ingelsson E. COX II inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib Eur Heart J 2011 doi:10.1093/eurheartj/ehr421
- ↑ Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbøl EL, Sørensen R, Folke F, Buch P, Gadsbøll N, Rasmussen S, Poulsen HE, Køber L, Madsen M, Torp-Pedersen C Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure Arch Intern Med. 2009;169(2):141-149
